Sanofi India Limited (SANOFI) Fair Value & Analysis
Healthcare · IN · Market cap ₹80.0B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price +6.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹3,097 – ₹5,905 · fair‑value band ₹2,129 – ₹3,845 · the ₹3,425 price screens above the ₹3,004 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sanofi India Limited (SANOFI) currently trades at ₹3,425, while our model-based Fair Value estimate is ₹3,004 — implying the stock looks roughly 12.3% overvalued today. We read business quality at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Sanofi India Limited generated revenue of ₹17.7B at a net margin of 17.5%. Revenue declined 11.9% year over year. It earns a return on equity of 40.6%. The balance sheet holds a net cash position of ₹2.6B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sanofi India Limited reported revenue of ₹18.4B in FY2025 versus ₹29.6B in FY2021, a compound −11.2%/yr. Reported net income was ₹3.3B in FY2025, compounding −23.3%/yr from FY2021.
Is SANOFI fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sanofi India Limited (SANOFI) undervalued?
What is the fair value of SANOFI?
What is the quality score of SANOFI?
What is the revenue of Sanofi India Limited (SANOFI)?
What is the net profit margin of SANOFI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.